Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

Revenues for J. B. Chemicals & Pharmaceuticals Limited are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 3.79000
forwardPE 28.98220
debtToEquity 1.07500
earningsGrowth 0.18900
revenueGrowth 0.08400
grossMargins 0.66546
operatingMargins 0.24441
trailingEps 45.35000
forwardEps 0.00000

JBCHEPHARM's current ratio of 3.79, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as JBCHEPHARM has enough cash and current assets to handle its immediate liabilities comfortably.
J. B. Chemicals & Pharmaceuticals Limited's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
J. B. Chemicals & Pharmaceuticals Limited's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

Throughout its recent performance, J. B. Chemicals & Pharmaceuticals Limited's price has been consistently close to the lower range of projected values. This suggests that the company may face challenges in achieving higher valuations in the eyes of investors.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


There were 68 JBCHEPHARM stock sales, with market price at 1725.8625039493336.The period under consideration saw no sell transactions.The recent trend of increased buying at JBCHEPHARM's current price levels may indicate a favorable market sentiment. This could point to a positive outlook for the stock, as investors show growing confidence through higher buy activity.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


Analysts have been favoring JBCHEPHARM with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning JBCHEPHARM as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.